Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome

Abstract:  Objective: Patients with hyperleukocytic leukaemia were graded according to the severity of symptoms possibly caused by leukostasis to evaluate the effectiveness of therapy and to test the relative contribution of blast type and count of blasts and promyelocytes in the development of leukostasis syndrome. Methods: Ninety‐five patients (59 male, 36 female, median age 52 yr) with hyperleukocytic leukaemia [leukocytes above 50 × 109/L, 48 acute myeloid leukaemia (AML), 31 chronic myeloid leukaemia (CML), 13 acute lymphoblastic leukaemia (ALL), three chronic myelomonocytic leukaemia (CMML)] were grouped according to the presence or absence and severity of neurologic, pulmonary and other symptoms into four categories (no, possible, probable and highly probable leukostasis syndrome). Age, white blood count (WBC), haemoglobin, blast count and total of blasts plus promyelocytes of these groups were compared by Mann–Whitney U‐test. Results: Patients with myeloid leukaemia (AML M1/M2, CML) which scored as highly probable leukostasis showed significantly higher WBC (P = 0.011), lower haemoglobin (P = 0.004), higher peripheral blast counts (P = 0.004) and higher total of peripheral blasts plus promyelocytes (P < 0.001) compared with the lower probability groups. In leukaemia involving the monocytic lineage (AML M4/M5, CMML) no significant differences were found in any of these factors between patients with highly probable leukostasis and the other patients. Conclusions: Our results show that a four‐stage clinical grading scale is a valuable tool for analysing hyperleukocytic patient populations and evaluate the effectiveness of therapy more precisely. We further demonstrate that the mechanisms of leukostasis are different in myeloid leukaemia as compared with leukaemia with involvement of the monocytic lineage.

[1]  A. Órfão,et al.  CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review , 2004, Leukemia.

[2]  G. Amir,et al.  Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis , 2002, American journal of hematology.

[3]  D. Hossfeld E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[4]  M. Bissell,et al.  Leukocytoreduction for acute leukemia. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[5]  P. Vyas,et al.  Pathology and genetics: Tumours of haematopoietic and lymphoid tissues , 2001 .

[6]  K. Oshimi,et al.  A minor E-selectin ligand, CD65, is critical for extravascular infiltration of acute myeloid leukemia cells. , 2001, Leukemia research.

[7]  J. Strahilevitz,et al.  Pulmonary leukostasis: Role of perfusion lung scan in diagnosis and follow up , 2001, American journal of hematology.

[8]  S. Mustjoki,et al.  Intercellular adhesion molecule‐1 in extravasation of normal mononuclear and leukaemia cells , 2001, British journal of haematology.

[9]  M. Schapira,et al.  Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. , 2001, Blood.

[10]  J. Falkenburg,et al.  Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells: implications for adoptive immunotherapy. , 2000, Experimental hematology.

[11]  P. Porcu,et al.  Hyperleukocytic Leukemias and Leukostasis: A Review of Pathophysiology, Clinical Presentation and Management , 2000, Leukemia & lymphoma.

[12]  P. Lacor,et al.  Different expression of adhesion molecules on CD34+ cells in AML and B‐lineage ALL and their normal bone marrow counterparts , 1999, European journal of haematology.

[13]  G. Ehninger,et al.  Relations between IL-3-induced proliferation and in vitro cytokine secretion of bone marrow cells from AML patients. , 1999, Cytokine.

[14]  J. Magaud,et al.  Differential adhesiveness between blood and marrow leukemic cells having similar pattern of VLA adhesion molecule expression. , 1998, Leukemia research.

[15]  N. Heerema,et al.  Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate , 1997, British journal of haematology.

[16]  M. Reuss-Borst,et al.  Differential expression of adhesion molecules in acute leukemia. , 1995, Leukemia.

[17]  W. Rosenstrauch,et al.  Hypoxaemia in patients with hyperleukocytosis: true or spurious, and clinical implications. , 1993, Leukemia research.

[18]  T. Horie,et al.  Myeloblastoma formation in acute myeloid leukemia. , 1992, Leukemia research.

[19]  F. Soares,et al.  Pulmonary leukostasis without hyperleukocytosis: A clinicopathologic study of 16 cases , 1992, American journal of hematology.

[20]  M. Keating,et al.  Acute myeloblastic leukemia with hyperleukocytosis: Risk factors for early mortality in induction , 1988, American journal of hematology.

[21]  A. Nagler,et al.  Acute respiratory failure in hyperleukocytotic acute myeloid leukemia: The role of perfusion lung scintigraphy , 1988, American journal of hematology.

[22]  M. van Buchem,et al.  Pulmonary leukostasis: radiologic-pathologic study. , 1987, Radiology.

[23]  J. Dutcher,et al.  Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Rowe,et al.  5 Hyperleukocytic leukaemia: rheological and clinical features and management , 1987 .

[25]  R. Larson,et al.  Acral lividosis--a sign of myeloproliferative diseases. Hyperleukocytosis syndrome in chronic myelogenous leukemia. , 1987, Archives of dermatology.

[26]  D. Catovsky,et al.  Priapism complicating chronic granulocytic leukemia , 1980, American journal of hematology.

[27]  T. J. Myers,et al.  Hyperviscosity in chronic granulocytic leukemia , 1980, Cancer.

[28]  P. Suratt,et al.  Pseudohypoxemia secondary to leukemia and thrombocytosis. , 1979, The New England journal of medicine.

[29]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[30]  R. Collins,et al.  INTRAVASCULAR LEUKOCYTE THROMBI AND AGGREGATES AS A CAUSE OF MORBIDITY AND MORTALITY IN LEUKEMIA , 1974, Medicine.

[31]  H. M. Marvin Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. , 1964 .

[32]  J. Forrester,et al.  DIFFERENTIAL EXPRESSION OF ADHESION MOLECULES IN ACUTE SYMPATHETIC OPHTHALMITIS , 1994 .

[33]  J. Rowe,et al.  Hyperleukocytic leukaemia: rheological and clinical features and management. , 1987, Bailliere's clinical haematology.

[34]  J. Rowe,et al.  Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. , 1982, Blood.

[35]  C. L. Ruemke Laboratory aids. Variability of results in differential cell counts on blood smears. , 1960, Triangle; the Sandoz journal of medical science.